Active Pharmaceutical Ingredient API News and Research

RSS

AMRI purchases Gadea Pharmaceutical Group for $174 million

AMRI today announced that it has acquired all the outstanding shares of Gadea Pharmaceutical Group, a privately-held company located in Valladolid, Spain, specializing in technically complex active pharmaceutical ingredients (APIs) and finished drug product.

16 Jul 2015

Proscia’s cloud-based platform allows clinicians, hospitals to make faster and more accurate cancer diagnosis

Proscia, a cloud-delivered solutions provider for digital pathology, today announced the release of a series of new features including Proscia Connect.

1 Jul 2015

Egalet reports positive results from Category 3 abuse-deterrent intranasal HAL study

Egalet Corporation today announced positive results from a Category 3 intranasal human abuse liability (HAL) study of Egalet-001, an abuse-deterrent, extended-release, oral morphine formulation in late-stage clinical development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate.

29 Jun 2015

ScinoPharm Taiwan, Raffles PharmaTech collaborate to manufacture Celecoxib

ScinoPharm Taiwan, Ltd. and Raffles PharmaTech announced today the collaboration to manufacture "Celecoxib," a non-steroidal and anti-inflammatory analgesic active pharmaceutical ingredient (API).

22 Jun 2015

Pulmatrix completes previously announced merger and closes $10 million in private placement

Pulmatrix, Inc., previously known as Ruthigen, Inc., today announced the completion of its previously announced merger, effective June 15, 2015, and the closing of a private placement generating aggregate gross proceeds of $10.0 million. Participants in the private placement included pre-merger investors in Pulmatrix such as funds affiliated with 5AM Ventures, ARCH Venture Partners and Polaris Partners, as well as funds affiliated with Altitude Life Science Ventures.

16 Jun 2015

DSM Sinochem Pharmaceuticals supports WHO’s ‘Call to Action’ on antimicrobial resistance

Following the Global Health Summit in Uppsala (Sweden) on 2-3 June, 2015, DSM Sinochem Pharmaceuticals pledged its commitment to the WHO’s ‘Call to Action’ on antimicrobial resistance issued at the Summit. One of the biggest opportunities to maintain the effectiveness and availability of antibiotics is responsible waste management, to date a highly undervalued dimension in the debate around resistance. DSP promised to use its expertise and influence in this area to help curb antimicrobial resistance.

16 Jun 2015

Can-Fite BioPharma receives Notice of Allowance for patent covering manufacturing method of CF101 drug

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today announced the U.S. Patent & Trademark Office has issued a Notice of Allowance to the Company for an important manufacturing method patent for its drug candidate CF101.

10 Jun 2015

EMR Direct's phiMail Server software achieves ONC-HIT 2014 Edition Modular Certification

EMR Direct, a Health Information Service Provider (HISP) and leading developer of Direct messaging software for the secure exchange of Protected Health Information (PHI) over the Internet, announced today that its phiMail Server software has achieved Office of the National Coordinator for Health Information Technology (ONC-HIT) 2014 Edition Modular Certification via Drummond Group LLC, an Authorized Certification Body (ACB).

8 Jun 2015

Category 1 findings support robust abuse-deterrent features of Egalet-002 for management of severe pain

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced positive top-line results from Category 1 abuse-deterrent studies for Egalet-002, an abuse-deterrent, extended-release, oral oxycodone-based product in development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate.

1 Jun 2015

ELC Group signs landmark deal with Chinese pharmaceutical giant

ELC Group, one of the fastest-growing providers of regulatory affairs services, today announces that it has been awarded a 1.5 million Euro contract by one of China’s biggest pharmaceutical companies.

24 Apr 2015

Aptuit increases API capacity to meet increased demand for integrated candidate-to-IND solutions

Dr. Jonathan Goldman, CEO, Aptuit LLC, announced that Aptuit has increased its global capacity for Active Pharmaceutical Ingredient (API) Manufacture due to increased demand for API, and for its integrated and comprehensive candidate-to-IND development solution.

3 Apr 2015

AMRI plans to close its API manufacturing facility in Holywell, U.K.

AMRI announced today that it has decided to close its Holywell, U.K. facility following a consultation process with employee representatives.

3 Apr 2015

Dipexium Pharmaceuticals reports strong financial results for year ended December 31, 2014

Dipexium Pharmaceuticals, Inc., a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad spectrum, topical antibiotic peptide, today announced operational, clinical and financial results for the year ended December 31, 2014.

24 Mar 2015

Keas announces launch of Health Hub for self-insured employers

Keas, the health management leader, today announced the launch of Health Hub, the first Health Management platform for self-insured employers.

18 Mar 2015

Revolutionary Oral-B Bluetooth-enabled toothbrush, App launched at Mobile World Congress 2015

Oral-B, the worldwide leader in oral care, unveils improvements to its App that connects to its highest performing toothbrushes, by creating seamless brushing routines and allowing for expanded professional guidance, at the 2015 annual GSMA Mobile World Congress meeting in Barcelona, Spain.

2 Mar 2015

Shire announces acquisition of Meritage Pharma

Shire plc and Meritage Pharma, Inc. announced today that Shire has acquired Meritage, a privately-held company, for an upfront fee of $70 million and additional contingent payments based on the achievement of development and regulatory milestones.

24 Feb 2015

Novasep selected to commercially biomanufacture Celladon's Mydicar API

Novasep, a leading supplier of services and technologies for the life sciences industry, today announces that it has entered into an agreement with Celladon, a clinical-stage biotechnology company. Novasep will prepare to supply the drug substance for MYDICAR®.

19 Feb 2015

Carpathia introduces beta program for Healthcare Community Cloud Service

Carpathia, a trusted cloud operator and leading provider of hybrid cloud services and managed hosting, today launched the beta program for Healthcare Community Cloud Service, an Infrastructure-as-a-Service solution that offers healthcare providers and affiliated service companies access to a compliant and scalable cloud infrastructure, purpose-built to help customers manage risk and ensure compliance with the Health Insurance Portability and Accountability Act and Health Information Technology for Economic and Clinical Health regulations.

18 Feb 2015

AMRI optimizes global operations to improve continuous supply chain across its businesses

AMRI today announced that it has implemented several changes to further optimize global business operations in order to enhance continuity from early development through to commercial supply and accelerate the company's global growth objectives.

12 Feb 2015

AMRI reports financial and operating results for Q4 and FY 2014

AMRI today reported financial and operating results for the fourth quarter and full year ended December 31, 2014.